For AML patients with oncogenic combinations driving their illness, the KMT2A combination is a molecular marker that can be leveraged for delicate MRD detection.” Investigators developed an unique bead digital PCR assay enabling sensitive KMT2A fusion detection with the 5 most common fusion partners. They benchmarked the assay in human cell lines and patient samples to demonstrate specific and delicate KMT2A blend detection.The assay finds these combinations by partitioning cDNA particles into microfluidic beads that are assayed with primers and probes that only produce a positive signal when combination transcripts are present. Private investigators were able to combine several primer/probe sets targeting various fusions into a pooled combination detection reagent.
For AML patients with oncogenic fusions driving their disease, the KMT2A blend is a molecular marker that can be leveraged for delicate MRD detection.” Investigators developed an unique bead digital PCR assay making it possible for delicate KMT2A fusion detection with the five most typical fusion partners. They benchmarked the assay in human cell lines and client samples to demonstrate delicate and specific KMT2A combination detection.The assay detects these fusions by segmenting cDNA particles into microfluidic beads that are assayed with primers and probes that just produce a positive signal when combination records are present.
